|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2001-1-11
|
|
pubmed:abstractText |
The aim was to determine the maximum tolerated dose (MTD) and recommended dose of irinotecan hydrochloride (CPT-11) in combination with a 14-day continuous infusion of etoposide in patients with refractory advanced lung cancer (LC), especially small cell lung cancer (SCLC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
0368-2811
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
487-93
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11155918-Adenocarcinoma,
pubmed-meshheading:11155918-Aged,
pubmed-meshheading:11155918-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:11155918-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11155918-Camptothecin,
pubmed-meshheading:11155918-Carcinoma, Small Cell,
pubmed-meshheading:11155918-Carcinoma, Squamous Cell,
pubmed-meshheading:11155918-Drug Administration Schedule,
pubmed-meshheading:11155918-Etoposide,
pubmed-meshheading:11155918-Female,
pubmed-meshheading:11155918-Humans,
pubmed-meshheading:11155918-Infusions, Intravenous,
pubmed-meshheading:11155918-Lung Neoplasms,
pubmed-meshheading:11155918-Male,
pubmed-meshheading:11155918-Maximum Tolerated Dose,
pubmed-meshheading:11155918-Middle Aged
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Phase I study of a weekly infusion of irinotecan hydrochloride (CPT-11) and a 14-day continuous infusion of etoposide in patients with lung cancer: JCOG trial 9408.
|
|
pubmed:affiliation |
Division of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
